CD274 and neoplasm: In fact, Avelumab failed to show survival advantage over docetaxel in patients with platinum treated NSCLC when all patients (i.e., with PD-L1 tumor expression of ≥1%) were included but survival advantage was observed in exploratory analysis when patients were stratified based on PD-L1 expression on their tumors (65).